Seshu Tyagarajan Sells 14,322 Shares of Candel Therapeutics, Inc. (NASDAQ:CADL) Stock

Candel Therapeutics, Inc. (NASDAQ:CADL) CTO Seshu Tyagarajan sold 14,322 shares of the company’s stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $7.22, for a total transaction of $103,404.84. Following the sale, the chief technology officer now directly owns 96,790 shares in the company, valued at approximately $698,823.80. The trade was a 12.89 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Seshu Tyagarajan also recently made the following trade(s):

• On Friday, November 29th, Seshu Tyagarajan sold 20,392 shares of Candel Therapeutics stock. The shares were sold at an average price of $4.56, for a total transaction of $92,987.52.

Candel Therapeutics Stock Down 13.4 %

Candel Therapeutics stock traded down $1.03 during trading on Friday, reaching $6.66. The stock had a trading volume of 1,899,373 shares, compared to its average volume of 1,683,500. Candel Therapeutics, Inc. has a 52-week low of $1.16 and a 52-week high of $14.60. The stock has a market cap of $216.32 million, a PE ratio of -3.85 and a beta of -1.20. The business has a 50 day moving average price of $6.58 and a 200 day moving average price of $6.27.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and set a $19.00 target price (up from $11.00) on shares of Candel Therapeutics in a research note on Wednesday, December 18th.

Hedge Funds Weigh In On Candel Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of CADL. FMR LLC acquired a new position in Candel Therapeutics in the third quarter valued at approximately $46,000. Geode Capital Management LLC grew its position in shares of Candel Therapeutics by 12.8% in the 3rd quarter. Geode Capital Management LLC now owns 448,997 shares of the company’s stock valued at $3,112,000 after buying an additional 51,111 shares during the last quarter. Barclays PLC grew its position in shares of Candel Therapeutics by 327.1% in the 3rd quarter. Barclays PLC now owns 28,688 shares of the company’s stock valued at $199,000 after buying an additional 21,971 shares during the last quarter. State Street Corp lifted its position in Candel Therapeutics by 4.1% in the third quarter. State Street Corp now owns 492,005 shares of the company’s stock valued at $3,410,000 after acquiring an additional 19,207 shares during the last quarter. Finally, Cubist Systematic Strategies LLC purchased a new stake in Candel Therapeutics in the second quarter valued at $162,000. Institutional investors and hedge funds own 13.93% of the company’s stock.

Candel Therapeutics Company Profile

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.